Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pancrelipase is a highly purified mixture of pancreatic enzymes—**lipase**, **amylase**, and **protease**—extracted from porcine pancreatic glands. It acts as a **digestive enzyme replacement therapy** for patients with exocrine pancreatic insufficiency, aiding in the breakdown of dietary fats, proteins, and carbohydrates to improve absorption and nutrition. The principal mechanism of action is direct enzyme supplementation, compensating for impaired pancreatic secretion due to cystic fibrosis, chronic pancreatitis, post-pancreatectomy, pancreatic cancer, or other causes. Developed and approved as a protein-based therapy, pancrelipase is available in multiple oral formulations for use in infants, children, and adults[3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pancrelipase (Janssen Pharmaceutical).